KRAS mutations drive tumor survival, growth, and immune escape in colorectal, non-small cell lung, and pancreatic ductal adenocarcinomas by reprogramming cancer cell metabolism and reshaping metabolic interactions within the tumor microenvironment (141). The gene discussed is KRAS; the disease is neoplasm.